A Phase II Single-Blind Placebo-Controlled Sequential Treatment Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Donepezil with Solifenacin in Patients with Alzheimer's Disease Type Dementia
Martin Farlow, MD
Primary Investigator
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to find out what the maximum tolerated dose (MTD) of donepezil when given with solifenacin and to evaluate the safety and tolerability of this combination, but the effects on signs and symptoms of Alzheimer?s disease will also be evaluated.
Description
The purpose of this study is to find out what the maximum tolerated dose (MTD) of donepezil when given with solifenacin and to evaluate the safety and tolerability of this combination, but the effects on signs and symptoms of Alzheimer?s disease will also be evaluated.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's Disease Type Dementia
-
Age: Between 50 Years - 79 Years
-
Gender: All